ReviewCells2019
Mesenchymal Stem Cells for Perianal Crohn's Disease.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Efficacy and safety of tumor necrosis factor-α inhibitors and mesenchymal stem cells in the treatment of fistulizing Crohn's disease: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Effect of mesenchymal stromal cells-derived extracellular vesicles as a treatment to heal diabetic wounds: A meta-analysis.International wound journal · 2023Pooled it
- Stem cell transplantation for induction of remission in medically refractory Crohn's disease.The Cochrane database of systematic reviews · 2022Pooled it
- MSC-Derived Extracellular Vesicles to Heal Diabetic Wounds: a Systematic Review and Meta-Analysis of Preclinical Animal Studies.Stem cell reviews and reports · 2022Pooled it
- Efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn's disease: a pilot study.Stem cell research & therapy · 2023Trial
- Evidence outside the box: Minimally invasive treatment for anal fistula.World journal of gastrointestinal surgery · 2025Review
- NDP52 and its emerging role in pathogenesis.Cell death & disease · 2025Review
- Sequential Applications of Adipose Tissue-derived Stem Cells Enhance Healing in Complex Wounds: Experimental Model.Plastic and reconstructive surgery. Global open · 2025Article
- Enabling Mesenchymal Stromal Cells and Their Extracellular Vesicles Clinical Availability-A Technological and Economical Evaluation.Journal of extracellular biology · 2025Article
- Harnessing Mesenchymal Stromal Cells for Advanced Wound Healing: A Comprehensive Review of Mechanisms and Applications.International journal of molecular sciences · 2024Review
- Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study.Wiener klinische Wochenschrift · 2024Article
- A Comprehensive Exploration of Therapeutic Strategies in Inflammatory Bowel Diseases: Insights from Human and Animal Studies.Biomedicines · 2024Review
- Synergistic therapeutic approach for hemorrhoids: integrating mesenchymal stem cells with diosmin-hesperidin to target tissue edema and inflammation.Archives of medical science : AMS · 2024Article
- Article
- The Future of Advanced Therapies for Pediatric Crohn's Disease.Paediatric drugs · 2023Article
- Crohn's disease: an update.Clinical medicine (London, England) · 2023Article
- Where Are We and Where to Next?-The Future of Perianal Crohn's Disease Management.Journal of clinical medicine · 2023Review
- Novel Approach in Rectovaginal Fistula Treatment: Combination of Modified Martius Flap and Autologous Micro-Fragmented Adipose Tissue.Biomedicines · 2023Article
- Enhancement of hMSC In Vitro Proliferation by Surface Immobilization of a Heparin-Binding Peptide.Molecules (Basel, Switzerland) · 2023Article
- A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perianal fistulizing Crohn's disease (PFCD) is associated with significant morbidity and might negatively impact the quality of life of CD patients. In the last two decades, the management of PFCD has evolved in terms of the multidisciplinary approach involving gastroenterologists and colorectal surgeons. However, the highest fistula healing rates, even combining surgical and anti-TNF agents, reaches 50% of treated patients. More recently, the administration of mesenchymal stem cells (MSCs) have shown notable promising results in the treatment of PFCD. The aim of this review is to describe the rationale and the possible mechanism of action of MSC application for PFCD and the most recent results of randomized clinical trials. Furthermore, the unmet needs of the current administration process and the expected next steps to improve the outcomes will be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.